Sebastien Gouard
Overview
Explore the profile of Sebastien Gouard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M, et al.
Cancers (Basel)
. 2019 Sep;
11(9).
PMID: 31480470
Personalized medicine represents a major goal in oncology. It has its underpinning in the identification of biomarkers with diagnostic, prognostic, or predictive values. Nowadays, the concept of biomarker no longer...
12.
Bailly C, Gouard S, Guerard F, Chalopin B, Carlier T, Faivre-Chauvet A, et al.
Int J Mol Sci
. 2019 May;
20(10).
PMID: 31137758
Although positron emission tomography (PET) imaging with 18-Fluorodeoxyglucose (F-FDG) is a promising technique in multiple myeloma (MM), the development of other radiopharmaceuticals seems relevant. CD138 is currently used as a...
13.
Koumeir C, De Nadal V, Cherubini R, Cherel M, Garrido E, Gouard S, et al.
Radiat Prot Dosimetry
. 2019 Jan;
183(1-2):270-273.
PMID: 30668799
The cyclotron ARRONAX can deliver different types of particles (protons, deuterons, alpha-particles) in an energy range up to 68 MeV. One of its six experimental halls is dedicated to studying...
14.
Foubert F, Gouard S, Sai-Maurel C, Cherel M, Faivre-Chauvet A, Goldenberg D, et al.
Oncotarget
. 2018 Jun;
9(44):27502-27513.
PMID: 29938001
Purpose: The aim of this study was to compare the performances pretargeted immunoPET Ga-PETimaging (Ga-pPET) with anti carcino-embryonic antigen (CEA) and anti-histamine-succinyl-glycine (HSG) recombinant humanized bispecific monoclonal antibody (TF2) and...
15.
Le Bihan T, Navarro A, Le Bris N, Saec P, Gouard S, Haddad F, et al.
Org Biomol Chem
. 2018 Apr;
16(23):4261-4271.
PMID: 29701218
In view of the excellent copper(ii) and 64-copper(ii) complexation of a TE1PA ligand, a monopicolinate cyclam, in both aqueous medium and in vivo, we looked for a way to make...
16.
Bailly C, Gouard S, Lacombe M, Saec P, Chalopin B, Bourgeois M, et al.
Oncotarget
. 2018 Mar;
9(10):9061-9072.
PMID: 29507674
Purpose: Although recent data from the literature suggest that PET imaging with [18]-Fluorodeoxyglucose (F-FDG) is a promising technique in multiple myeloma (MM), the development of other radiopharmaceuticals seems relevant. CD138...
17.
Niaudet C, Bonnaud S, Guillonneau M, Gouard S, Gaugler M, Dutoit S, et al.
Cell Signal
. 2017 Feb;
33:10-21.
PMID: 28179144
The p38 MAPK signaling pathway is essential in the cellular response to stress stimuli, in particular in the endothelial cells that are major target of external stress. The importance of...
18.
Menager J, Gorin J, Fichou N, Gouard S, Morgenstern A, Bruchertseifer F, et al.
Med Sci (Paris)
. 2016 May;
32(4):362-9.
PMID: 27137693
Alpha-radioimmunotherapy (α-RIT) is a targeted anti-tumor therapy using usually a monoclonal antibody specific for a tumor antigen that is coupled to an α-particle emitter. α-emitters represent an ideal tool to...
19.
Dorso L, Bigot-Corbel E, Abadie J, Diab M, Gouard S, Bruchertseifer F, et al.
PLoS One
. 2016 Mar;
11(3):e0151330.
PMID: 26982495
Background: Short-term toxicological evaluations of alpha-radioimmunotherapy have been reported in preclinical assays, particularly using bismuth-213 (213Bi). Toxicity is greatly influenced not only by the pharmacokinetics and binding specificity of the...
20.
Derrien A, Gouard S, Maurel C, Gaugler M, Bruchertseifer F, Morgenstern A, et al.
Front Med (Lausanne)
. 2016 Jan;
2:88.
PMID: 26734610
Purpose: Ovarian peritoneal carcinomatosis is a pathology for which effective cures are currently lacking. New research protocols seek to eradicate residual micrometastases following cytoreductive surgery by using hyperthermic intraperitoneal chemotherapy...